Quarterly ResultAug 11, 2026, 05:13 PM
Aardvark Therapeutics Q2 Net Loss $(14.39)M; Cash $73.85M
AI Summary
Aardvark Therapeutics reported a net loss of $(14.39) million for Q2 2026 and $(35.98) million for the six months ended June 30, 2026, an increase from the prior year. The company's cash and cash equivalents increased to $73.85 million, while total assets decreased to $81.46 million. Aardvark believes its current capital is sufficient for at least one year and has established an At-The-Market (ATM) facility for up to $150 million to raise additional funds.
Key Highlights
- Net loss for Q2 2026 was $(14.39) million, compared to $(14.37) million in Q2 2025.
- Net loss for the six months ended June 30, 2026, was $(35.98) million, up from $(23.68) million in 2025.
- Cash and cash equivalents increased to $73.85 million as of June 30, 2026, from $47.05 million at year-end 2025.
- Total assets decreased to $81.46 million as of June 30, 2026, from $117.18 million at year-end 2025.
- Accumulated deficit grew to $(151.89) million as of June 30, 2026.
- Research and development expenses for six months increased to $27.02 million from $20.90 million.
- Entered into an ATM facility in March 2026 to sell up to $150.0 million of common stock.
- Board approved a proposal to reprice certain stock options, pending stockholder approval.
Price Impact
More from AARD